Home Protein Tyrosine Kinase Trk receptor

Trk receptor

Other Protein Tyrosine Kinase Related Inhibitors

VEGFR EGFR c-Met PDGFR CSF-1R IGF-1R c-Kit ALK Tie-2 HER2

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S7998 Entrectinib (Rxdx-101) Entrectinib is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Entrectinib (RXDX-101) induces autophagy. Phase 2.
Leukemia, 2025, 10.1038/s41375-025-02682-8
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-25-0025
Verified customer review of Entrectinib (Rxdx-101)
S5860 Larotrectinib (LOXO-101) Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) is an ATP-competitive, oral administered and highly selective inhibitor of the tropomyosin-related kinase (TRK) family receptors.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Toxicol Lett, 2025, 406:31-37
Cancer Med, 2024, 13(12):e7393
S9662 UNC2025 UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. This compound also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.
iScience, 2024, 27(7):110226
Commun Biol, 2023, 6(1):916
Int J Mol Sci, 2023, 10.3390/ijms242115903
S1460 SP600125 SP600125 (Nsc75890) is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. This compound is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. It inhibits autophagy and activates apoptosis.
Nat Commun, 2025, 16(1):7156
Adv Sci (Weinh), 2025, 12(28):e2502634
Adv Sci (Weinh), 2025, 12(36):e00028
Verified customer review of SP600125
S7745 ANA-12 ANA-12 is a selective TrkB antagonist with Kd of 10 nM and 12 μM for the high and low affinity sites, respectively.
Antioxidants (Basel), 2025, 14(3)344
Geroscience, 2025, 10.1007/s11357-025-01783-7
Neurochem Res, 2025, 50(4):234
Verified customer review of ANA-12
S7960 Larotrectinib sulfate Larotrectinib sulfate is an oral potent and selective ATP-competitive inhibitor of tropomyosin receptor kinases (TRK). Larotrectinib inhibition of TRKs induces cellular apoptosis and G1 cell-cycle arrest.
iScience, 2024, 27(10):110862
Oncogenesis, 2023, 12(1):8
Front Pharmacol, 2022, 13:1032975
Verified customer review of Larotrectinib sulfate
S2891 GW441756 GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2. This compound produces a relevant increase of caspase-3 that leads to apoptosis.
Cell Res, 2025, 10.1038/s41422-025-01098-4
Neurochem Int, 2025, 191:106072
Cells, 2023, 12(3)373
Verified customer review of GW441756
S8319 7,8-Dihydroxyflavone 7,8-Dihydroxyflavone (7,8-DHF) acts as a potent and selective small-molecule agonist of the TrkB receptor (Kd ≈ 320 nM), the main signaling receptor of brain-derived neurotrophic factor (BDNF).
Int J Biol Sci, 2023, 19(16):5204-5217
International Journal of Biological Sciences, 2023, 5204-5217
Pharmacol Res, 2022, 176:106079
S7519 GNF-5837 GNF-5837 is a selective, and orally bioavailable pan-TRK inhibitor for TrkA, and TrkB with IC50 of 8 nM, and 12 nM, respectively.
J Neurochem, 2025, 169(8):e70194
Cell Rep, 2022, 41(11):111827
Clin Transl Oncol, 2021, 10.1007/s12094-021-02666-x
S6760 LM22B-10 LM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator. This compound selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.
Theranostics, 2024, 14(4):1561-1582
Theranostics, 2024, 1561-1582
Int J Mol Sci, 2024, 25(4)2408

Signaling Pathway Map